INVESTOR NEWS

May 13, 2026

Flaggemelding – Gentian Diagnostics ASA

Melding etter verdipapirhandelloven § 4-2 Oslo, 13 mai 2026 Vatne Capital AS, kontrollert av Runar Vatne, har..

May 13, 2026

Board resignation

Moss, 13 May 2026 Reference is made to the stock exchange release regarding Vatne Capital’s notification of..

May 13, 2026

Meldepliktig handel og endring i styret

Oslo, 13 mai 2026 Vatne Capital AS, et selskap kontrollert av Runar Vatne, har i dag overdratt samtlige..

May 06, 2026

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

May 06, 2026

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

May 06, 2026

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..

May 05, 2026

Gentian Diagnostics: Minutes from Annual General Meeting

Moss 5 May, 2026 Gentian Diagnostics ASA has today held its annual general meeting (AGM). All items on the..

Apr 29, 2026

Gentian Diagnostics: Invitation to presentation of first quarter results

Gentian Diagnostics ASA will present its first quarter 2026 results on 6 May 2026 at 09.00 CEST. The..

Apr 20, 2026

Gentian Diagnostics renews long term faecal calprotectin partnership with Bühlmann Laboratories

Moss, 20 April 2026 Gentian Diagnostics, a fast-growing developer and manufacturer of high-quality diagnostic..

Apr 13, 2026

Gentian Diagnostics: Notice of annual general meeting

Gentian Diagnostics ASA’s annual general meeting will be held on Tuesday 5 May 2026 at 11:00 at the company’s..